EGFR and non-small cell lung carcinoma: There continues to be significant developments in the field of EGFR mutation-positive NSCLC, a third-generation of EGFR-TKIs is already seeking to improve outcomes, especially with osimertinib in patients resistant to EGFR-TKIs due to T790M mutations.